Suppr超能文献

急性冠状动脉综合征患者循环单核细胞中 CD36 和 MSR1 的高表达。

Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes.

机构信息

Department of Animal Physiology and Development, Faculty of Biology, Adam Mickiewicz University, Umultowska 89 Str., 61-614 Poznan, Poland.

出版信息

Protein J. 2012 Aug;31(6):511-8. doi: 10.1007/s10930-012-9431-8.

Abstract

Acute Coronary Syndromes (ACS) are a group of disorders caused by the significant reduction of circulation in coronary arteries. The most common reason of the dysfunction is a blood clot formed in place of plaque rupture. The role of scavenger receptors in development and progression of atherosclerosis has been confirmed in many animal experiments, however the knowledge about contribution of the receptors in the development of ACS symptoms in humans still remains insufficient. The aim of this work was to define the expression of two scavenger receptors: CD36 and MSR1 in monocytes of patients with ACS after the onset of symptoms and after the 6 months of treatment. The analysis of CD36 and MSR1 expression was carried out with the use of real-time PCR and flow cytometry. Analyses of lipid and glucose concentration in blood and the level of inflammatory markers in plasma were performed additionally for all ACS patients. All data obtained during the research were analyzed using statistical tests, such as Mann Whitney test, Wilcoxon test, or correlation. In all patients with symptoms of ACS the amount of CD36 and MSR1 mRNA in circulating monocytes, as well as the density of both receptors on the cells surface was significantly higher. Re-analysis of subjects after 6 months of treatment, showed a significant decrease in the CD36 and MSR1 expression in all patients who received atorvastatin. The results of presented studies demonstrate that both investigated receptors are involved in the development and/or progression of ACS.

摘要

急性冠状动脉综合征(ACS)是一组由冠状动脉循环显著减少引起的疾病。功能障碍最常见的原因是斑块破裂部位形成的血栓。在许多动物实验中已经证实了清道夫受体在动脉粥样硬化的发展和进展中的作用,然而,关于受体在人类 ACS 症状发展中的作用的知识仍然不足。本工作的目的是确定 ACS 症状发作后和治疗 6 个月后患者单核细胞中两种清道夫受体(CD36 和 MSR1)的表达。使用实时 PCR 和流式细胞术分析 CD36 和 MSR1 的表达。对所有 ACS 患者的血液脂质和葡萄糖浓度以及血浆中炎症标志物水平进行了额外分析。使用统计检验(如曼-惠特尼检验、威尔科克森检验或相关性检验)对研究过程中获得的所有数据进行分析。在所有 ACS 症状患者中,循环单核细胞中 CD36 和 MSR1 mRNA 的含量以及细胞表面两种受体的密度均显著升高。对治疗 6 个月后的患者重新分析显示,所有接受阿托伐他汀治疗的患者 CD36 和 MSR1 的表达均显著降低。本研究结果表明,两种研究的受体均参与 ACS 的发展和/或进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bdd/3397216/a7ce7465e146/10930_2012_9431_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验